X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 73.83 CNY -0.55% Market Closed
Market Cap: 30B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Xiamen Amoytop Biotech Co Ltd stock under the Base Case scenario is 130.9 CNY. Compared to the current market price of 73.83 CNY, Xiamen Amoytop Biotech Co Ltd is Undervalued by 44%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
130.9 CNY
Undervaluation 44%
Relative Value
Price
X
Worst Case
Base Case
Best Case

Valuation Multiples

10.2
P/S
P/S
Price to Sales
10.2
vs History
69
vs Industry
36
Median 3Y
10.3
Median 5Y
11.2
Industry
6.7
Forward
7.9
More Details
34.1
P/E
P/E
Price to Earnings
34.1
vs History
95
vs Industry
3
Median 3Y
41.9
Median 5Y
56.9
Industry
21.9
Forward
25.3
More Details
53.8
P/OCF
P/OCF
Price to OCF
53.8
vs History
53
vs Industry
3
Median 3Y
46.8
Median 5Y
54.9
Industry
19.2
More Details
89.4
P/FCFE
P/FCFE
Price to FCFE
89.4
vs History
74
vs Industry
2
Median 3Y
130.8
Median 5Y
187
Industry
22.5
More Details
11.8
P/B
P/B
Price to Book Value
11.8
vs History
55
vs Industry
5
Median 3Y
11.7
Median 5Y
12.3
Industry
2.4
More Details
10
EV/S
EV/S
Enterprise Value to Sales
10
vs History
63
vs Industry
31
Median 3Y
10
Median 5Y
10.9
Industry
7.1
Forward
7.7
More Details
10.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.7
vs History
68
vs Industry
31
Median 3Y
10.8
Median 5Y
11.9
Industry
9
More Details
29
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
29
vs History
88
vs Industry
3
Median 3Y
33.5
Median 5Y
40
Industry
3.7
Forward
19.2
More Details
29
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
29
vs History
88
vs Industry
4
Median 3Y
33.5
Median 5Y
40
Industry
3.4
Forward
22.1
More Details
52.6
EV/OCF
EV/OCF
Enterprise Value to OCF
52.6
vs History
52
vs Industry
3
Median 3Y
45.5
Median 5Y
53.3
Industry
4.3
More Details
90.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
90.1
vs History
77
vs Industry
1
Median 3Y
117.8
Median 5Y
184.1
Industry
3.4
More Details
12.6
EV/IC
EV/IC
Enterprise Value to IC
12.6
vs History
68
vs Industry
12
Median 3Y
13.4
Median 5Y
14.2
Industry
4.5
More Details

Multiples Across Competitors

Competitors Multiples
Xiamen Amoytop Biotech Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Xiamen Amoytop Biotech Co Ltd
SSE:688278
30B CNY 10.2 34.1 29 29
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 349 427.2 -168 010.6 -204 018.4 -201 690.3
US
Abbvie Inc
NYSE:ABBV
325.9B USD 5.8 76.9 15.3 23.1
US
Amgen Inc
NASDAQ:AMGN
143B USD 4.2 24.1 13.3 21.9
US
Gilead Sciences Inc
NASDAQ:GILD
120.7B USD 4.2 20.2 8.9 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
109.2B USD 9.8 -110.4 23.4 24.5
US
Epizyme Inc
F:EPE
94.1B EUR 1 992.9 -508.5 -553.8 -539
AU
CSL Ltd
ASX:CSL
115.9B AUD 4.9 27 16.7 20.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
57.1B USD 4.1 12.7 11.3 12.7
US
Seagen Inc
F:SGT
39.3B EUR 19.2 -58.9 -63.4 -57.2
NL
argenx SE
XBRU:ARGX
30.3B EUR 15.5 40.8 -2 304.7 -1 545.2
P/S Multiple
Revenue Growth P/S to Growth
CN
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Average P/S: 3 213 772.5
10.2
31%
0.3
FR
Pharnext SCA
OTC:PNEXF
35 349 427.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.2
4%
1
US
Gilead Sciences Inc
NASDAQ:GILD
4.2
3%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
1 992.9
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.1
5%
0.8
US
S
Seagen Inc
F:SGT
19.2
30%
0.6
NL
argenx SE
XBRU:ARGX
15.5
39%
0.4
P/E Multiple
Earnings Growth PEG
CN
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Average P/E: 33.7
34.1
36%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -168 010.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
76.9
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.1
44%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
20.2
187%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -110.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -508.5 N/A N/A
AU
CSL Ltd
ASX:CSL
27
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
10%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.9 N/A N/A
NL
argenx SE
XBRU:ARGX
40.8
28%
1.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Average EV/EBITDA: 16.8
29
32%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -204 018.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.3
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
8.9
7%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
18%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -553.8 N/A N/A
AU
CSL Ltd
ASX:CSL
16.7
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.3
14%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.4 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 304.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Average EV/EBIT: 20.6
29
33%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 690.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
21.9
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
11%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -539 N/A N/A
AU
CSL Ltd
ASX:CSL
20.9
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
13%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 545.2 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.